Premium
Temozolomide Treatment for Pediatric Refractory Anaplastic Ependymoma with Low MGMT Protein Expression
Author(s) -
Komori Kazutoshi,
Yanagisawa Ryu,
Miyairi Yosuke,
Sakashita Kazuo,
Shiohara Masaaki,
Fujihara Ikuko,
Morita Daisuke,
Nakamura Tomohiko,
Ogiso Yoshifumi,
Sano Kenji,
Shirahata Mitsuaki,
Fukuoka Kohei,
Ichimura Koichi,
Shigeta Hiroaki
Publication year - 2016
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.25696
Subject(s) - medicine , temozolomide , ependymoma , refractory (planetary science) , oncology , protein expression , glioblastoma , cancer research , pathology , genetics , astrobiology , biology , physics , gene
The benefit of postoperative chemotherapy for anaplastic ependymoma remains unknown. We report two pediatric patients with refractory anaplastic ependymoma treated with temozolomide (TMZ). We did not detect O 6 ‐methylguanine‐DNA methyltransferase (MGMT) promoter methylation in tumor samples; however, MGMT protein expression was low. With TMZ treatment, one patient had a 7‐month complete remission; the other, stable disease for 15 months. Three other patients did not respond to TMZ; two had high and one low MGMT expression, and two showed no MGMT promoter methylation. These findings suggest that TMZ may be effective for pediatric refractory anaplastic ependymoma with low MGMT protein expression. Pediatr Blood Cancer © 2015 Wiley Periodicals, Inc.